Open AccessAssessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation
Author(s) -
Wanyuan Cui,
Prudence A. Francis,
Sherene Loi,
Martha Hickey,
Catharyn Stern,
Lumine Na,
Ann H. Partridge,
Sibylle Loibl,
Richard A. Anderson,
Karla J. Hutt,
Louise Keogh,
KellyAnne Phillips
Publication year - 2021
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djab111
Subject(s) - medicine , oncology , clinical trial , breast cancer , ovarian cancer , clinical endpoint , cancer , adverse effect , gynecology
Loss of ovarian function is a recognized adverse effect of chemotherapy for breast cancer and of great importance to patients. Little is known about the ovarian toxicity of newer cancer treatments. This study examined whether breast cancer clinical trials include assessment of the impact of trial interventions on ovarian function.